179 related articles for article (PubMed ID: 33862582)
21. High EGFR mRNA expression is a prognostic factor for reduced survival in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.
Fujita H; Ohuchida K; Mizumoto K; Itaba S; Ito T; Nakata K; Yu J; Kayashima T; Hayashi A; Souzaki R; Tajiri T; Onimaru M; Manabe T; Ohtsuka T; Tanaka M
Int J Oncol; 2011 Mar; 38(3):629-41. PubMed ID: 21243324
[TBL] [Abstract][Full Text] [Related]
22. A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer.
El-Rayes BF; Philip PA; Sarkar FH; Shields AF; Ferris AM; Hess K; Kaseb AO; Javle MM; Varadhachary GR; Wolff RA; Abbruzzese JL
Invest New Drugs; 2011 Aug; 29(4):694-9. PubMed ID: 20107864
[TBL] [Abstract][Full Text] [Related]
23. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial.
Hammel P; Huguet F; van Laethem JL; Goldstein D; Glimelius B; Artru P; Borbath I; Bouché O; Shannon J; André T; Mineur L; Chibaudel B; Bonnetain F; Louvet C;
JAMA; 2016 May; 315(17):1844-53. PubMed ID: 27139057
[TBL] [Abstract][Full Text] [Related]
24. Phase II study of gemcitabine and erlotinib as adjuvant therapy for patients with resected pancreatic cancer.
Bao PQ; Ramanathan RK; Krasinkas A; Bahary N; Lembersky BC; Bartlett DL; Hughes SJ; Lee KK; Moser AJ; Zeh HJ
Ann Surg Oncol; 2011 Apr; 18(4):1122-9. PubMed ID: 21104328
[TBL] [Abstract][Full Text] [Related]
25. Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3.
da Cunha Santos G; Dhani N; Tu D; Chin K; Ludkovski O; Kamel-Reid S; Squire J; Parulekar W; Moore MJ; Tsao MS
Cancer; 2010 Dec; 116(24):5599-607. PubMed ID: 20824720
[TBL] [Abstract][Full Text] [Related]
26. The combination of HLA-B*15:01 and DRB1*15:01 is associated with gemcitabine plus erlotinib-induced interstitial lung disease in patients with advanced pancreatic cancer.
Nishimura M; Toyoda M; Takenaka K; Imamura Y; Chayahara N; Kiyota N; Mukohara T; Kotake T; Tsuji A; Saito K; Saito Y; Minami H
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1165-70. PubMed ID: 27100735
[TBL] [Abstract][Full Text] [Related]
27. SAHA, an HDAC inhibitor, overcomes erlotinib resistance in human pancreatic cancer cells by modulating E-cadherin.
Park SJ; Kim SM; Moon JH; Kim JH; Shin JS; Hong SW; Shin YJ; Lee DH; Lee EY; Hwang IY; Kim JE; Kim KP; Hong YS; Lee WK; Choi EK; Lee JS; Jin DH; Kim TW
Tumour Biol; 2016 Apr; 37(4):4323-30. PubMed ID: 26493999
[TBL] [Abstract][Full Text] [Related]
28. A retrospective analysis of VeriStrat status on outcome of a randomized phase II trial of first-line therapy with gemcitabine, erlotinib, or the combination in elderly patients (age 70 years or older) with stage IIIB/IV non-small-cell lung cancer.
Stinchcombe TE; Roder J; Peterman AH; Grigorieva J; Lee CB; Moore DT; Socinski MA
J Thorac Oncol; 2013 Apr; 8(4):443-51. PubMed ID: 23370367
[TBL] [Abstract][Full Text] [Related]
29. Erlotinib plus gemcitabine versus gemcitabine for pancreatic cancer: real-world analysis of Korean national database.
Shin S; Park CM; Kwon H; Lee KH
BMC Cancer; 2016 Jul; 16():443. PubMed ID: 27400734
[TBL] [Abstract][Full Text] [Related]
30. Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer.
Kulke MH; Blaszkowsky LS; Ryan DP; Clark JW; Meyerhardt JA; Zhu AX; Enzinger PC; Kwak EL; Muzikansky A; Lawrence C; Fuchs CS
J Clin Oncol; 2007 Oct; 25(30):4787-92. PubMed ID: 17947726
[TBL] [Abstract][Full Text] [Related]
31. SPARC expression in resected pancreatic cancer patients treated with gemcitabine: results from the CONKO-001 study.
Sinn M; Sinn BV; Striefler JK; Lindner JL; Stieler JM; Lohneis P; Bischoff S; Bläker H; Pelzer U; Bahra M; Dietel M; Dörken B; Oettle H; Riess H; Denkert C
Ann Oncol; 2014 May; 25(5):1025-32. PubMed ID: 24562449
[TBL] [Abstract][Full Text] [Related]
32. Relevance of Sp Binding Site Polymorphism in WWOX for Treatment Outcome in Pancreatic Cancer.
Schirmer MA; Lüske CM; Roppel S; Schaudinn A; Zimmer C; Pflüger R; Haubrock M; Rapp J; Güngör C; Bockhorn M; Hackert T; Hank T; Strobel O; Werner J; Izbicki JR; Johnsen SA; Gaedcke J; Brockmöller J; Ghadimi BM
J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26857392
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the 'Arbeitsgemeinschaft Internistische Onkologie'.
Haas M; Siveke JT; Schenk M; Lerch MM; Caca K; Freiberg-Richter J; Fischer von Weikersthal L; Kullmann F; Reinacher-Schick A; Fuchs M; Kanzler S; Kunzmann V; Ettrich TJ; Kruger S; Westphalen CB; Held S; Heinemann V; Boeck S
Eur J Cancer; 2018 May; 94():95-103. PubMed ID: 29549862
[TBL] [Abstract][Full Text] [Related]
34. Comorbidity, age and overall survival in patients with advanced pancreatic cancer - results from NCIC CTG PA.3: a phase III trial of gemcitabine plus erlotinib or placebo.
Vickers MM; Powell ED; Asmis TR; Jonker DJ; Hilton JF; O'Callaghan CJ; Tu D; Parulekar W; Moore MJ
Eur J Cancer; 2012 Jul; 48(10):1434-42. PubMed ID: 22119354
[TBL] [Abstract][Full Text] [Related]
35. Human equilibrative nucleoside transporter 1 is not predictive for gemcitabine efficacy in advanced pancreatic cancer: translational results from the AIO-PK0104 phase III study with the clone SP120 rabbit antibody.
Ormanns S; Heinemann V; Raponi M; Isaacson J; Laubender RP; Haas M; Kruger S; Kleespies A; Mann E; Bartosiewicz M; Kirchner T; Boeck S
Eur J Cancer; 2014 Jul; 50(11):1891-9. PubMed ID: 24857044
[TBL] [Abstract][Full Text] [Related]
36. Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety results of a phase IIb randomised study from the Spanish TTD Collaborative Group.
Irigoyen A; Gallego J; Guillén Ponce C; Vera R; Iranzo V; Ales I; Arévalo S; Pisa A; Martín M; Salud A; Falcó E; Sáenz A; Manzano Mozo JL; Pulido G; Martínez Galán J; Pazo-Cid R; Rivera F; García García T; Serra O; Fernández Parra EM; Hurtado A; Gómez Reina MJ; López Gomez LJ; Martínez Ortega E; Benavides M; Aranda E;
Eur J Cancer; 2017 Apr; 75():73-82. PubMed ID: 28222309
[TBL] [Abstract][Full Text] [Related]
37. Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy.
Kim ST; Lim DH; Jang KT; Lim T; Lee J; Choi YL; Jang HL; Yi JH; Baek KK; Park SH; Park YS; Lim HY; Kang WK; Park JO
Mol Cancer Ther; 2011 Oct; 10(10):1993-9. PubMed ID: 21862683
[TBL] [Abstract][Full Text] [Related]
38. DLL4 expression is a prognostic marker and may predict gemcitabine benefit in resected pancreatic cancer.
Drouillard A; Puleo F; Bachet JB; Ouazzani S; Calomme A; Demetter P; Verset G; Van Laethem JL; Maréchal R
Br J Cancer; 2016 Nov; 115(10):1245-1252. PubMed ID: 27755532
[TBL] [Abstract][Full Text] [Related]
39. Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression.
Crane CH; Varadhachary GR; Yordy JS; Staerkel GA; Javle MM; Safran H; Haque W; Hobbs BD; Krishnan S; Fleming JB; Das P; Lee JE; Abbruzzese JL; Wolff RA
J Clin Oncol; 2011 Aug; 29(22):3037-43. PubMed ID: 21709185
[TBL] [Abstract][Full Text] [Related]
40. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.
Wu YL; Lee JS; Thongprasert S; Yu CJ; Zhang L; Ladrera G; Srimuninnimit V; Sriuranpong V; Sandoval-Tan J; Zhu Y; Liao M; Zhou C; Pan H; Lee V; Chen YM; Sun Y; Margono B; Fuerte F; Chang GC; Seetalarom K; Wang J; Cheng A; Syahruddin E; Qian X; Ho J; Kurnianda J; Liu HE; Jin K; Truman M; Bara I; Mok T
Lancet Oncol; 2013 Jul; 14(8):777-86. PubMed ID: 23782814
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
